Aggressive Lymphomas
From the Journals
Hodgkin lymphoma survival has nearly tripled since the 1950s
Five-year relative survival for Hodgkin lymphoma increased 189% over the approximately 60 years from the early 1950s to 2013.
From the Journals
Circulating DNA catches lymphoma relapse early
New findings from researchers at Stanford signal a win for ‘liquid biopsy,’ the measurement of tumor DNA circulating in the blood.
News
Study provides new insight into B-cell metabolism
Research published in Nature Immunology helps explain how B-cell metabolism adapts to different environments.
News
Study quantifies 5-year survival rates for blood cancers
A new study shows that 5-year survival rates for US patients with hematologic malignancies have increased greatly since the 1950s, but there is...
News
Improving the efficacy of obinutuzumab
Preclinical research suggests that immune stimulation through Toll-like receptor 7 (TLR7) agonism can enhance the efficacy of obinutuzumab in...
News
Overcoming glucocorticoid resistance in lymphoma
Targeting RUNX1 could combat glucocorticoid resistance in patients with lymphoma, according to research published in the Journal of Cellular...
News
FDA approves ibrutinib to treat rel/ref MZL
The US Food and Drug Administration (FDA) has approved the Bruton’s tyrosine kinase inhibitor ibrutinib (Imbruvica®) for the treatment of marginal...
Video
VIDEO: First multicenter trial of CAR T cells shows response in DLBCL
SAN DIEGO - Aggressive, refractory non-Hodgkin lymphomas responded to anti-CD19 chimeric antigen receptor T cells in ZUMA-1, the first...
News
Prolonged work-related stress linked to NHL, other cancers in men
New research suggests that prolonged exposure to work-related stress may increase a man’s risk of several cancers.
News
Venetoclax approved to treat CLL in Australia
The Australian Therapeutic Goods Administration (TGA) has approved the BCL-2 inhibitor venetoclax (Venclexta™, formerly ABT-199) for use in...
News
Combo granted orphan designation for CLL
The US Food and Drug Administration (FDA) has granted orphan drug designation for the combination of TG-1101 (ublituximab) and TGR-1202 for the...